tldrdailynews.com logo

FDA casts doubt on Capricor's Duchenne stem cell therapy

1 min read
Source: STAT
FDA casts doubt on Capricor's Duchenne stem cell therapy
Photo: STAT
TL;DR Summary

The FDA says Capricor's Duchenne stem cell therapy deramiocel did not meet the Phase 3 trial endpoints, contradicting the company’s earlier claim of success and ahead of an upcoming hearing.

Topics:business#capricor#deramiocel#duchenne#fda#health#phase3
Share this article
  1. Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug  STAT
  2. Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait?  Yahoo Finance
  3. FDA staff flags data concerns about Capricor's therapy; shares plunge  Reuters
  4. Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)  MarketBeat
  5. FDA staff flags concerns for Capricor’s Duchenne heart disease therapy  WTVB

Reading Insights

Total Reads

1

Unique Readers

8

Time Saved

2 min

vs 3 min read

Condensed

93%

412 → 30 words

Want the full story? Read the original article

Read on STAT